Deep-Learning for Rapid Estimation of the Out-of-Field Dose in External Beam Photon Radiation Therapy - A Proof of Concept.

Journal: International journal of radiation oncology, biology, physics
Published Date: Mar 28, 2024

Abstract

PURPOSE: The dose deposited outside of the treatment field during external photon beam radiation therapy treatment, also known as out-of-field dose, is the subject of extensive study as it may be associated with a higher risk of developing a second cancer and could have deleterious effects on the immune system that compromise the efficiency of combined radio-immunotherapy treatments. Out-of-field dose estimation tools developed today in research, including Monte Carlo simulations and analytical methods, are not suited to the requirements of clinical implementation because of their lack of versatility and their cumbersome application. We propose a proof of concept based on deep learning for out-of-field dose map estimation that addresses these limitations.

Authors

  • Nathan Benzazon
    U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.
  • Alexandre Carré
    U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.
  • François de Kermenguy
    Unité Mixte de Recherche (UMR) 1030 Radiothérapie Moléculaire et Innovation Thérapeutique, ImmunoRadAI, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Stéphane Niyoteka
    U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France.
  • Pauline Maury
    Unité Mixte de Recherche (UMR) 1030 Radiothérapie Moléculaire et Innovation Thérapeutique, ImmunoRadAI, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Julie Colnot
    Unité Mixte de Recherche (UMR) 1030 Radiothérapie Moléculaire et Innovation Thérapeutique, ImmunoRadAI, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France; THERYQ, PMB-Alcen, Peynier, France.
  • Meissane M'hamdi
    Unité Mixte de Recherche (UMR) 1030 Radiothérapie Moléculaire et Innovation Thérapeutique, ImmunoRadAI, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Mohammed El Aichi
    Unité Mixte de Recherche (UMR) 1030 Radiothérapie Moléculaire et Innovation Thérapeutique, ImmunoRadAI, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Cristina Veres
    Unité Mixte de Recherche (UMR) 1030 Radiothérapie Moléculaire et Innovation Thérapeutique, ImmunoRadAI, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Rodrigue Allodji
    Unité Mixte de Recherche (UMR) 1018 Centre de Recherche en épidémiologie et Santé des Populations (CESP), Radiation Epidemiology Team, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France.
  • Florent de Vathaire
    Unité Mixte de Recherche (UMR) 1018 Centre de Recherche en épidémiologie et Santé des Populations (CESP), Radiation Epidemiology Team, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France.
  • David Sarrut
    Université de Lyon, CREATIS, CNRS UMR5220, Inserm U1294, INSA-Lyon, Université Lyon 1, Lyon, France.
  • Neige Journy
    Unité Mixte de Recherche (UMR) 1018 Centre de Recherche en épidémiologie et Santé des Populations (CESP), Radiation Epidemiology Team, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France.
  • Claire Alapetite
    Department of Radiotherapy, Institut Curie, Paris, France.
  • Vincent Gregoire
    Department of Radiation Oncology, Centre Leon Berard, Lyon, France.
  • Eric Deutsch
    Gustave Roussy Cancer Campus, Villejuif, France.
  • Ibrahima Diallo
    Unité Mixte de Recherche (UMR) 1030 Radiothérapie Moléculaire et Innovation Thérapeutique, ImmunoRadAI, Inserm, Université Paris-Saclay, Institut Gustave Roussy, Villejuif, France; Department of Radiation Oncology, Institut Gustave Roussy, Villejuif, France.
  • Charlotte Robert
    U1030 Molecular Radiotherapy, Paris-Sud University - Gustave Roussy - Inserm - Paris-Saclay University, Villejuif, France; Department of Medical Physics, Gustave Roussy - Paris-Saclay University, Villejuif, France. Electronic address: ch.robert@gustaveroussy.fr.

Keywords

External Resources

Popular Topics
Recent Journals